---
title: "Bank of America Securities Keeps Their Buy Rating on Kymera Therapeutics (KYMR)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273850672.md"
description: "Bank of America Securities analyst Tazeen Ahmad has maintained a Buy rating on Kymera Therapeutics (KYMR) with a price target of $112.00. Ahmad, who focuses on the Healthcare sector, has an average return of 2.6% and a 52.93% success rate on his stock recommendations. Additionally, TD Cowen's Marc Frahm also issued a Buy rating for Kymera Therapeutics, while TipRanks reiterated a Hold rating on January 13."
datetime: "2026-01-27T13:28:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273850672.md)
  - [en](https://longbridge.com/en/news/273850672.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273850672.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273850672.md) | [繁體中文](https://longbridge.com/zh-HK/news/273850672.md)


# Bank of America Securities Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Kymera Therapeutics today and set a price target of $112.00.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Ahmad covers the Healthcare sector, focusing on stocks such as Neurocrine, Ascendis Pharma, and Rhythm Pharmaceuticals. According to TipRanks, Ahmad has an average return of 2.6% and a 52.93% success rate on recommended stocks.

In addition to Bank of America Securities, Kymera Therapeutics also received a Buy from TD Cowen’s Marc Frahm in a report issued on January 15. However, on January 13, TipRanks – OpenAI reiterated a Hold rating on Kymera Therapeutics (NASDAQ: KYMR).

### Related Stocks

- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [Kymera Therapeutics, Inc. (KYMR.US)](https://longbridge.com/en/quote/KYMR.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [13:06 ETHall Render Represents Centurion Foundation in Rhode Island Hospital Acquisition, Preserving Essential Health Care Services](https://longbridge.com/en/news/278427087.md)
- [Incannex Healthcare Prices $10 Mln Potential Offering Of Shares And Warrants; Stock Down](https://longbridge.com/en/news/278896600.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/en/news/278556054.md)
- [Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | INTS Stock News](https://longbridge.com/en/news/278874097.md)
- [Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference](https://longbridge.com/en/news/278285380.md)